Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment

Table 2

Development in disease activity assessed by faecal calprotectin (mg/kg) in paediatric and adult patients with inflammatory bowel disease.

	Crohn’s disease				Ulcerative colitis
	Calprotectin: <250/>250		OR of remission (95% CI)	values	Calprotectin: <250/>250		OR of remission (95% CI)	values
	Paediatric	Adult			Paediatric	Adult
Visit 1	27/20	47/13	0.4 (0.2-0.9)	0.03	11/12	11/12	1.0 (0.3-3.2)	1.0
Visit 2	32/15	49/11	0.5 (0.2-1.2)	0.1	20/3	17/6	2.4 (0.5-10.9)	0.3
Visit 3	35/12	46/14	0.9 (0.4-2.2)	0.8	20/3	12/11	6.1 (1.4-26.4)	0.01
Visit 4	32/15	48/12	0.5 (0.2-1.3)	0.2	19/4	17/6	1.7 (0.4-7.0)	0.5

Odds ratio of remission in paediatric patients compared with adult patients. CD: Crohn’s disease; UC: ulcerative colitis; IBD: inflammatory bowel disease; OR: odds ratio. Calprotectin levels: mg/kg. Not all records contained calprotectin measurements at all visits.